MX2023013802A - Inhibidores de tirosina quinasa de fgfr para el tratamiento de tumores solidos avanzados. - Google Patents
Inhibidores de tirosina quinasa de fgfr para el tratamiento de tumores solidos avanzados.Info
- Publication number
- MX2023013802A MX2023013802A MX2023013802A MX2023013802A MX2023013802A MX 2023013802 A MX2023013802 A MX 2023013802A MX 2023013802 A MX2023013802 A MX 2023013802A MX 2023013802 A MX2023013802 A MX 2023013802A MX 2023013802 A MX2023013802 A MX 2023013802A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- fgfr2
- carcinoma
- fgfr
- patient
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title abstract 3
- 208000037844 advanced solid tumor Diseases 0.000 title 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 101150081124 FGFR gene Proteins 0.000 abstract 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 2
- 230000010558 Gene Alterations Effects 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 abstract 1
- 206010073087 Malignant sweat gland neoplasm Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 abstract 1
- 206010061934 Salivary gland cancer Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000000728 Thymus Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 229950004444 erdafitinib Drugs 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 208000029824 high grade glioma Diseases 0.000 abstract 1
- 208000030173 low grade glioma Diseases 0.000 abstract 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 abstract 1
- 201000011614 malignant glioma Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000000281 malignant syringoma Diseases 0.000 abstract 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000003913 parathyroid carcinoma Diseases 0.000 abstract 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 206010073373 small intestine adenocarcinoma Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente descripción se describen métodos para tratar el cáncer, dichos métodos comprenden administrar una cantidad terapéuticamente efectiva de erdafitinib a un paciente que ha sido diagnosticado con cáncer y que alberga al menos una fusión del receptor de factor de crecimiento de fibroblastos (FGFR) seleccionada de FGFR2-CCDC102A, FGFR2-CCDC147, FGFR2-ENOX1, FGFR2-GPHN, FGFR2-LCN10, FGFR2-PDE3A, FGFR2-RANBP2, FGFR3-ENOX1, FGFR3-TMEM247, IGSF3-FGFR1, RHPN2- FGFR1 y RRM2B-FGFR2. También se describen en la presente descripción métodos para tratar el cáncer que comprenden: evaluar una muestra biológica de un paciente que ha sido diagnosticado con cáncer y que alberga al menos una alteración genética del FGFR, en donde el cáncer es colangiocarcinoma, glioma de alto grado, cáncer de páncreas, cáncer de pulmón de células no pequeñas (NSCLC) escamosas, NSCLC no escamosas, cáncer de mama, cáncer colorrectal, cáncer de endometrio, cáncer gástrico, cáncer de ovario, cáncer de primario desconocido, cáncer de cuello uterino, cáncer de células escamosas de cabeza y cuello, cáncer de esófago, glioma de bajo grado, cáncer de próstata, cáncer de glándulas salivales, carcinoma de células basales, cáncer de timo, adenocarcinoma de intestino delgado, carcinoma hepatocelular, carcinoma anexial microquístico, carcinoma espinocelular, tumor del estroma gastrointestinal o carcinoma paratiroideo; y administrar una dosis terapéuticamente efectiva de un inhibidor del FGFR al paciente si al menos una alteración génica del FGFR está presente en la muestra.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190602P | 2021-05-19 | 2021-05-19 | |
| US202163242857P | 2021-09-10 | 2021-09-10 | |
| US202163253316P | 2021-10-07 | 2021-10-07 | |
| PCT/EP2022/063629 WO2022243467A1 (en) | 2021-05-19 | 2022-05-19 | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013802A true MX2023013802A (es) | 2023-12-06 |
Family
ID=82067489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013802A MX2023013802A (es) | 2021-05-19 | 2022-05-19 | Inhibidores de tirosina quinasa de fgfr para el tratamiento de tumores solidos avanzados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000858A1 (es) |
| EP (1) | EP4340840A1 (es) |
| JP (1) | JP2024518612A (es) |
| KR (1) | KR20240009465A (es) |
| AU (1) | AU2022277796A1 (es) |
| BR (1) | BR112023023935A2 (es) |
| CA (1) | CA3217517A1 (es) |
| MX (1) | MX2023013802A (es) |
| TW (1) | TW202313038A (es) |
| WO (1) | WO2022243467A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017990A (zh) * | 2023-08-28 | 2023-11-10 | 温州医科大学 | 厄达替尼联用度洛西汀或舍曲林在制备治疗肿瘤的药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| WO2015150900A2 (en) * | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| SMT202200177T1 (it) | 2014-09-26 | 2022-05-12 | Janssen Pharmaceutica Nv | Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr |
| CA3141869A1 (en) * | 2019-05-28 | 2020-12-03 | Qed Therapeutics, Inc. | Methods of treating cholangiocarcinoma |
-
2022
- 2022-05-19 JP JP2023571447A patent/JP2024518612A/ja active Pending
- 2022-05-19 US US18/561,347 patent/US20250000858A1/en active Pending
- 2022-05-19 KR KR1020237043394A patent/KR20240009465A/ko active Pending
- 2022-05-19 TW TW111118772A patent/TW202313038A/zh unknown
- 2022-05-19 MX MX2023013802A patent/MX2023013802A/es unknown
- 2022-05-19 CA CA3217517A patent/CA3217517A1/en active Pending
- 2022-05-19 WO PCT/EP2022/063629 patent/WO2022243467A1/en not_active Ceased
- 2022-05-19 BR BR112023023935A patent/BR112023023935A2/pt not_active Application Discontinuation
- 2022-05-19 AU AU2022277796A patent/AU2022277796A1/en active Pending
- 2022-05-19 EP EP22730734.5A patent/EP4340840A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4340840A1 (en) | 2024-03-27 |
| TW202313038A (zh) | 2023-04-01 |
| US20250000858A1 (en) | 2025-01-02 |
| BR112023023935A2 (pt) | 2024-01-30 |
| CA3217517A1 (en) | 2022-11-24 |
| AU2022277796A1 (en) | 2024-01-18 |
| JP2024518612A (ja) | 2024-05-01 |
| KR20240009465A (ko) | 2024-01-22 |
| WO2022243467A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains | |
| Irani et al. | A review of the profile of endothelin axis in cancer and its management | |
| Messersmith et al. | Targeting EGFR in colorectal cancer | |
| JP2010516770A5 (es) | ||
| Atreya et al. | Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches | |
| Hu et al. | USP22 promotes tumor progression and induces epithelial–mesenchymal transition in lung adenocarcinoma | |
| Le Bras et al. | Esophageal cancer: the latest on chemoprevention and state of the art therapies | |
| EA201790547A1 (ru) | Новые соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы | |
| Wang et al. | High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival | |
| NO20074366L (no) | Fremgangsmate for a behandle gefitmibresistent kreft | |
| Wang et al. | The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer | |
| Milano et al. | Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy | |
| IL273252B2 (en) | Compositions and methods for predicting response to napi2b-targeted therapy | |
| MX2023013802A (es) | Inhibidores de tirosina quinasa de fgfr para el tratamiento de tumores solidos avanzados. | |
| Thibault et al. | HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review | |
| Park et al. | High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer | |
| Luo et al. | Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer | |
| Teixidó et al. | ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines | |
| Zhu et al. | Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| Ansieau et al. | Failsafe program escape and EMT: a deleterious partnership | |
| Nelson et al. | An increasingly important therapeutic target: Part 2 Distribution of HER2/neu Overexpression and Gene Amplification by Organ, Tumor Site and Histology | |
| Hoffmann et al. | Endothelins and their receptors as biological markers for oral cancer | |
| Zhang et al. | CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway | |
| Masroor et al. | Clinical implication of EGF A61G polymorphism in the risk of non small cell lung adenocarcinoma patients: a case control study |